BC Extra | Dec 7, 2019
Company News

Dec. 6 Company Quick Takes: Alexion rebuffs activist’s push for sale; plus UCB, Genmab, Enzyvant, Biohaven

Under activist pressure, Alexion decides against proactive sale process  Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) rose 6% Friday, boosting the company’s market cap by $1.4 billion, after the company said in a statement that its...
BC Extra | Jun 14, 2019
Clinical News

June 14 Clinical Quick Takes: Chi-Med, BeiGene, UCB, Global Blood and more

Chi-Med’s surufatinib meets in Phase III for extra-pancreatic neuroendocrine tumors  Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said it is planning a pre-NDA meeting with China’s National Medical Products Administration (NMPA) after surufatinib (formerly sulfatinib) met...
BioCentury | Jan 9, 2018
Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
BC Week In Review | Dec 22, 2017
Clinical News

UCB's bimekizumab meets in Phase IIb for ankylosing spondylitis

UCB S.A. (Euronext:UCB) reported data from the Phase IIb BE AGILE trial in 303 patients with active ankylosing spondylitis showing that subcutaneous bimekizumab (UCB4940) every four weeks met the primary endpoint of a greater proportion...
BC Week In Review | Jul 28, 2017
Clinical News

UCB's bimekizumab meets in Phase IIb for psoriasis

UCB S.A. (Euronext:UCB) reported top-line data from the Phase IIb BE ABLE trial in 250 patients with moderate to severe chronic plaque psoriasis showing that subcutaneous bimekizumab (UCB4940) every 4 weeks met the primary endpoint...
BC Extra | Jul 21, 2017
Clinical News

UCB psoriasis candidate headed for Phase III

UCB S.A. (Euronext:UCB) said bimekizumab (UCB4940) led to 90% clearance of plaque psoriasis per the Psoriasis Area and Severity Index (PASI 90) in up to 79% of patients in the Phase IIb BE ABLE study,...
BC Week In Review | Jul 25, 2016
Clinical News

Bimekizumab: Phase Ib data

Top-line data from a double-blind, European Phase Ib trial in 52 patients with psoriatic arthritis who had inadequate responses to >=1 DMARD and/or 1 biologic showed that pooled data from the top 3 doses (n=30)...
BC Week In Review | Mar 4, 2013
Clinical News

UCB4940: Phase I started

UCB disclosed in its 2012 earnings that it began a Phase I trial of UCB4940. UCB Group (Euronext:UCB), Brussels, Belgium   Product: UCB4940   Business: Autoimmune   Molecular target: NA   Description: Undisclosed antibody-based product...
Items per page:
1 - 8 of 8